Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cyteir Therapeutics (CYT)
NASDAQ:CYT
RESEARCH TOOLSreports
Cyteir Therapeutics (CYT) Stock Price & Analysis
24 Followers
CYT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.65 - $3.19
Previous Close$3.01
Volume1.01M
Average Volume (3M)176.77K
Market Cap
$108.35M
Enterprise Value-$20.89M
Total Cash (Recent Filing)$129.24M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-3.2
Beta1.16
Next Earnings
May 02, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding35,998,068
10 Day Avg. Volume599,919
30 Day Avg. Volume176,767
Standard Deviation0.20
R-Squared0.00068
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.87
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.61
Forecast
1Y Price Target
$3.00Price Target Upside-0.66% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
Cyteir Therapeutics News
PremiumCompany Announcements
Cyteir Therapeutics Formalizes Dissolution and Asset Payout Plan
Ownership Overview
50.84% Insiders
8.92% Mutual Funds
31.21% Other Institutional Investors
9.03% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CYT FAQ
What was Cyteir Therapeutics’s price range in the past 12 months?
Cyteir Therapeutics lowest stock price was $1.65 and its highest was $3.19 in the past 12 months.
What is Cyteir Therapeutics’s market cap?
Currently, no data Available
When is Cyteir Therapeutics’s upcoming earnings report date?
Cyteir Therapeutics’s upcoming earnings report date is May 02, 2024 which is in 13 days.
How were Cyteir Therapeutics’s earnings last quarter?
Currently, no data Available
Is Cyteir Therapeutics overvalued?
According to Wall Street analysts Cyteir Therapeutics’s price is currently Overvalued.
Does Cyteir Therapeutics pay dividends?
Cyteir Therapeutics does not currently pay dividends.
What is Cyteir Therapeutics’s EPS estimate?
Cyteir Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyteir Therapeutics have?
Cyteir Therapeutics has 35,998,070 shares outstanding.
What happened to Cyteir Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cyteir Therapeutics?
Among the largest hedge funds holding Cyteir Therapeutics’s share is Western Standard Llc. It holds Cyteir Therapeutics’s shares valued at N/A.
---
Cyteir Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$3.00 (-0.66% Downside)
$3.00 (-0.66% Downside)
Hedge Fund Trend
Decreased
By 524.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $484.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
81.32%
12-Months-Change
Fundamentals
Return on Equity
-23.80%
Trailing 12-Months
Asset Growth
-18.98%
Trailing 12-Months
Company Description
Cyteir Therapeutics
Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing the next generation of precision oncology medicines that inhibit DNA damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. Its lead program, CYT-0851, as well as next-generation drug candidate CYT-1853, exploits a novel gain-of-function synthetically lethal relationship between overexpression of a family of DNA damaging genes called cytidine deaminases, and functional inhibition of homologous recombination, a DNA repair pathway critical for the survival of some cancers.
---
CYT Stock 12 Months Forecast
Average Price Target
$3.00
▼(-0.66% Downside)
Technical Analysis
Best Analysts Covering CYT
1 Year
1 Year Success Rate
1/4 ratings generated profit
1 Year Average Return
-49.35%
reiterated a buy rating 11 months ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -49.35% per trade.
---